rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

Maanddraad December

278 Posts
Pagina: 1 2 3 4 5 6 ... 14 »» | Laatste | Omlaag ↓
  3. MeawandMoo1 3 december 2008 02:20

    • MeawandMoo1

      Lid sinds: 22 jan 2006

      Laatste bezoek: 28 jul 2024

    • Aanbevelingen

      Ontvangen: 420

      Gegeven: 38

    •    Aantal posts: 459

    www.gavialliance.org/media_centre/pre...
    ......
    Responding to increased demand by poor countries to immunise children under five, the GAVI Alliance has committed to fund an additional US$ 134 million in new and continued programmes yesterday for vaccines against rotavirus, pneumococcal disease and Haemophilus influenzae type b (Hib).

    The programmes will support 11 countries and provide vaccines to an estimated 6.6 million children.
    .......
    Armenia, Bhutan, Cambodia, Laos, and Sao Tome will receive support to immunise approximately 2.9 million children with the life-saving Hib vaccine. It will be administered through three shots of a pentavalent vaccine that also includes antigens against diphtheria, tetanus, pertussis, and hepatitis B.
    .......
    Drie doses? helaas geen Quivaxem, neem ik aan.

    Since GAVI was launched in 2000, the number of poor countries that have accessed the Alliance’s life-saving support has skyrocketed. Requests from countries for hepatitis B vaccine, for example, have risen from nearly zero to more than 60 countries in just eight years.
  4. forum rang 4 harvester 3 december 2008 06:28

    • harvester

      Lid sinds: 01 apr 2004

      Laatste bezoek: 19 mrt 2025

    • Aanbevelingen

      Ontvangen: 2007

      Gegeven: 1890

    •    Aantal posts: 4.191

    Quinvaxem: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis in children.

    Lijkt anders volledig op penta als genoemd in persbericht GAVI.
  5. eddy59 3 december 2008 08:57

    • eddy59

      Lid sinds: 03 okt 2008

      Laatste bezoek: 20 mrt 2025

    • Aanbevelingen

      Ontvangen: 76

      Gegeven: 92

    •    Aantal posts: 1.034

    Crucell and Novavax Announce PER.C6(TM)
    Er stond vanochtend in de telegraaf dat DSM volgend jaar het middel gaat voordragen aan de FDA.
    Weet iemand hier meer over?
  6. [verwijderd] 3 december 2008 09:27

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    MeawandMoo1 schreef:

    .......
    Armenia, Bhutan, Cambodia, Laos, and Sao Tome will receive support to immunise approximately 2.9 million children with the life-saving Hib vaccine. It will be administered through three shots of a pentavalent vaccine that also includes antigens against diphtheria, tetanus, pertussis, and hepatitis B.
    .......
    Drie doses? helaas geen Quivaxem, neem ik aan.

    Is QV: drie injecties met een pentavalent. QV is fully liquid penta.
  7. [verwijderd] 3 december 2008 09:48

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    eddy59 schreef:

    Crucell and Novavax Announce PER.C6(TM)
    Er stond vanochtend in de telegraaf dat DSM volgend jaar het middel gaat voordragen aan de FDA.
    Weet iemand hier meer over?
    Bedoel je dit eddy?

    di 02 dec 2008, 08:05 DSM levert bestanddeel artrosemedicijn

    HEERLEN (AFN) - Chemieconcern DSM gaat een belangrijk bestanddeel produceren van een medicijn tegen artrose waar de Franse biofarmaceut Nicox aan werkt. Daartoe hebben de twee een overeenkomst getekend. Dat heeft Nicox dinsdag bekendgemaakt.

    Naar verwachting levert DSM het middel op grote schaal vanaf het vierde kwartaal volgend jaar. Nicox heeft het medicijn recent met succes getest op artrosepatiënten. Het bedrijf verwacht medio volgend jaar een aanvraag in te dienen bij de Amerikaanse toezichthouder Food and Drug Administration voor goedkeuring van het medicijn.

    Dirk
  12. aossa 3 december 2008 14:12

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 19 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

    NicOx S.A. (NYSE Euronext Paris: COX) today announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient). Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which recently achieved positive results in the third pivotal phase 3 study in osteoarthritis patients.

    Under the terms of the agreement, DSM will supply naproxcinod API for commercial purposes from its fine chemicals production site in Linz, Austria. DSM is one of the world's leading independent suppliers to the pharmaceutical industry, with some 40% of today's top-selling medicines in the world containing ingredients developed and produced by DSM. This follows the signature of an agreement with Capsugel in September 2008 for the commercial manufacture of naproxcinod oral capsules, which is widely recognized as the world leader in capsule manufacturing.

    Staffan Stromberg, Vice President of Technical Development and Operations at NicOx, commented: "The latest positive results observed in the 111 and 303 studies support our confidence in naproxcinod's blockbuster potential. We are therefore very pleased to have signed these contracts with global leaders in high capacity API and capsule production. We project these agreements should cover the high sales forecasts for the initial years of naproxcinod's commercialization that have been suggested by our market research."

    The agreement with DSM aims to secure commercial supplies of an appropriate scale to support the successful launch of naproxcinod. As per the agreement, NicOx envisages the first deliveries of significant quantities of commercial material being made from the fourth quarter of 2009 onwards. Following this agreement with DSM and the importance of cost control in the current economic environment, NicOx has ended its present API supply agreement with Archimica. At the point of termination, Archimica had met all contract milestones and was in full compliance with the other terms of the contract.

    Luca Mantovani, President & Business Unit Director at DSM Pharma Chemicals, declared: "We are happy to consolidate our relationship with NicOx through this agreement. Naproxcinod is an exciting compound and being part of its pre-launch and future commercialization plans is an interesting opportunity for DSM."

    On November 24, NicOx announced that the third pivotal phase 3 study for naproxcinod in osteoarthritis of the hip had met all three co-primary efficacy endpoints. Following the positive results from the 301 and 302 studies in osteoarthritis of the knee, 303 represents the third pivotal phase 3 study for naproxcinod to achieve p<0.001 on all three co-primary efficacy endpoints. In addition, naproxcinod 750 mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo in the 303 study.

    This followed the announcement of positive results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study) on November 4, where naproxcinod showed a statistically significant reduction in systolic blood pressure of 3.8 mmHg (p=0.011) compared to naproxen over the whole study period. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

    DSM - the Life Sciences and Materials Sciences Company

    Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on the NYSE Euronext Amsterdam. More information: www.dsm.com.

    NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

    Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs and symptoms of osteoarthritis. Naproxcinod has completed three pivotal phase 3 studies with positive results and the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) is projected for mid-2009.

    Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

    NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps).

    This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

    For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

    SOURCE NicOx
    www.fiercebiotech.com/node/42628/print
  14. Mr Greenspan 3 december 2008 14:32

    • Mr Greenspan

      Lid sinds: 22 nov 2000

      Laatste bezoek: 16 mrt 2025

    • Aanbevelingen

      Ontvangen: 2041

      Gegeven: 1872

    •    Aantal posts: 8.805

    quote:

    aad100 schreef:

    en weinig aanbod. Geen last van shorters. Heb de indruk dat die al een tijdje niet meer opereren.
    Shorters zien meer brood in aandelen van ondernemingen waar paniek of onzekerheid kan ontstaan, zoals banken of ondernemingen die schulden moeten herfinancieren. Crucell is financieel gezond en heeft ipc fundamenteel een aardige bodem. Dat valt lang niet voor elk aandeel te zeggen. Zonder de overname van Berna was Crucell zeker doelwit van shorters geweest in deze tijden.
  15. [verwijderd] 5 december 2008 09:06

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by restructuring. Some even have to suspend operations or file for bankruptcy.

    Er zijn kansen. Ontwikkelaars kopen (kosten drukken), STAR/PerC6 inbrengen, weer verkopen.
  16. [verwijderd] 5 december 2008 10:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Toch opvallend dat Crucell al dagen aardig stand houdt, of de beurs nu zakt of niet.......steeds een beetje hoger, langzaam maar zeker.....
  19. eddy59 5 december 2008 16:09

    • eddy59

      Lid sinds: 03 okt 2008

      Laatste bezoek: 20 mrt 2025

    • Aanbevelingen

      Ontvangen: 76

      Gegeven: 92

    •    Aantal posts: 1.034

    quote:

    Nx4nX schreef:

    Alle calls gaan scherp omlaag. En puts ook. Huh??
    Inderdaad, echt vreemd mijn calls dec09 €12,00 stonden bij een koers van € 9,00 op € 2,00 en nu op € 1.20.
    Er wordt een spelletje gespeeld om wat aandelen goedkoop los te peuteren. Wie heeft een mening over een andere stategie.
    Eddy
  20. aossa 5 december 2008 16:45

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 19 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    quote:

    eddy59 schreef:

    [quote=Nx4nX]
    Alle calls gaan scherp omlaag. En puts ook. Huh??
    [/quote]
    Inderdaad, echt vreemd mijn calls dec09 €12,00 stonden bij een koers van € 9,00 op € 2,00 en nu op € 1.20.
    Er wordt een spelletje gespeeld om wat aandelen goedkoop los te peuteren. Wie heeft een mening over een andere stategie.
    * rente gedaald (met 175 basispunten zelfs) => krijg je dus minder premie
    * aandeelkoers is langere tijd op nagenoeg zelfde koers blijven hangen, waardoor de impl.volatility afneemt
    * tijdwaarde die een beetje is afgenomen

    Nie neuten, wie in calls handelt moet de truuken van de foor kennen, anders afblijven !
  21. aossa 5 december 2008 16:54

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 19 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    &Last but not least ...

    De markt denkt misschien dat het weer omhoog kan !
278 Posts
Pagina: 1 2 3 4 5 6 ... 14 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.104
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.035
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.825
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.797
Aedifica 3 925
Aegon 3.258 323.033
AFC Ajax 538 7.088
Affimed NV 2 6.303
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.348
Air France - KLM 1.025 35.259
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.151
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.714
AMG 971 134.203
AMS 3 73
Amsterdam Commodities 305 6.743
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 492
Antonov 22.632 153.605
Aperam 92 15.043
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.794
Arcelor Mittal 2.034 320.929
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.583
ASML 1.766 109.741
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.819
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.442